138 related articles for article (PubMed ID: 17994286)
1. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.
Davies EH; Erikson A; Collin-Histed T; Mengel E; Tylki-Szymanska A; Vellodi A
J Inherit Metab Dis; 2007 Nov; 30(6):935-42. PubMed ID: 17994286
[TBL] [Abstract][Full Text] [Related]
2. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
[TBL] [Abstract][Full Text] [Related]
5. Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
Rice EO; Mifflin TE; Sakallah S; Lee RE; Sansieri CA; Barranger JA
Clin Genet; 1996 Mar; 49(3):111-8. PubMed ID: 8737974
[TBL] [Abstract][Full Text] [Related]
6. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
7. Cessation of enzyme replacement therapy in Gaucher disease.
Grinzaid KA; Geller E; Hanna SL; Elsas LJ
Genet Med; 2002; 4(6):427-33. PubMed ID: 12509713
[TBL] [Abstract][Full Text] [Related]
8. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
Goker-Alpan O; Hruska KS; Orvisky E; Kishnani PS; Stubblefield BK; Schiffmann R; Sidransky E
J Med Genet; 2005 Jun; 42(6):e37. PubMed ID: 15937077
[TBL] [Abstract][Full Text] [Related]
9. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.
Choy FY; Zhang W; Shi HP; Zay A; Campbell T; Tang N; Ferreira P
Blood Cells Mol Dis; 2007; 38(3):287-93. PubMed ID: 17196853
[TBL] [Abstract][Full Text] [Related]
10. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
12. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.
Cox-Brinkman J; van Breemen MJ; van Maldegem BT; Bour L; Donker WE; Hollak CE; Wijburg FA; Aerts JM
J Inherit Metab Dis; 2008 Dec; 31(6):745-52. PubMed ID: 18850301
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation.
Ida H; Rennert OM; Iwasawa K; Kobayashi M; Eto Y
Hum Genet; 1999; 105(1-2):120-6. PubMed ID: 10480365
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for Gaucher disease in Australia.
Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Gaucher Disease With Matched Sibling Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review.
Chavananon S; Sripornsawan P; Songthawee N; Chotsampancharoen T
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1153-e1155. PubMed ID: 33661172
[TBL] [Abstract][Full Text] [Related]
16. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
17. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.
Sawicka-Gutaj N; Machaczka M; Kulińska-Niedziela I; Bernardczyk-Meller J; Gutaj P; Sowiński J; Ruchała M
Ups J Med Sci; 2016 Aug; 121(3):192-5. PubMed ID: 27064303
[TBL] [Abstract][Full Text] [Related]
18. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
19. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
20. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
